NEUP (Neuphoria Therapeutics) Tariff Resilience Score: 5/10 (As of Jul. 02, 2026)


NEUP Neuphoria Therapeutics Inc NEUP
32 GF Score
Price $3.40
! 1 Warning Sign
View Full Analysis

What is Neuphoria Therapeutics Tariff Resilience Score?

Neuphoria Therapeutics NEUP -3.95% 32 Tariff Resilience Score is 5 as of Jul. 02, 2026. GuruFocus rates NEUP with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,374 Biotechnology companies, Neuphoria Therapeutics ranks better than 62.23% on this metric.

Neuphoria Therapeutics has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Neuphoria Therapeutics has Neuphoria Therapeutics Inc faces moderate tariff risks due to its reliance on imported raw materials for drug manufacturing. However, its ability to negotiate prices and explore alternative suppliers offers some mitigation.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Neuphoria Therapeutics might have Average Resilient.

Neuphoria Therapeutics  (NAS:NEUP) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Neuphoria Therapeutics Tariff Resilience Score Related Terms

NEUP vs PLRZ, SKYE, IGC: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Neuphoria Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuphoria Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Neuphoria Therapeutics's Tariff Resilience Score falls into.


NEUP
32GF Score
Neuphoria Therapeutics Inc NEUP
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Neuphoria Therapeutics (NEUP) has a Tariff Resilience Score of 5 as of Jul. 02, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Neuphoria Therapeutics ranks #519 out of 1374 companies in the Biotechnology industry, placing it in the top 37.8%.
Is Neuphoria Therapeutics' Tariff Resilience Score too high?
Neuphoria Therapeutics' current Tariff Resilience Score is 5. The Biotechnology industry median Tariff Resilience Score is 4.00. Neuphoria Therapeutics' value of 5 is 25% above this industry median. Based on the distribution chart, Neuphoria Therapeutics ranks #519 out of 1374 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Neuphoria Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neuphoria Therapeutics' Tariff Resilience Score compare to PLRZ and SKYE?
According to the Biotechnology industry distribution chart, Neuphoria Therapeutics ranks #519 out of 1374 companies for Tariff Resilience Score. This puts Neuphoria Therapeutics in the upper half of its industry. The industry median Tariff Resilience Score is 4.00. Neuphoria Therapeutics' value of 5 is 25% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,374 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuphoria Therapeutics's current Tariff Resilience Score of 5 is 25% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuphoria Therapeutics's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuphoria Therapeutics stock overvalued right now?
Neuphoria Therapeutics (NEUP) has a current Tariff Resilience Score of 5. The current Tariff Resilience Score is 5 and 25% above the Biotechnology industry median of 4.00. Neuphoria Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current Tariff Resilience Score is 5 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuphoria Therapeutics Business Description

Address 100 Summit Drive, Burlington, MA, USA, 01803
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.
32GF Score

Get the complete analysis for NEUP

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.40
Price